The FDA permanently appointed four leaders to key positions, including a new artificial intelligence role, while Google DeepMind released the AlphaGenome Atlas database. Meanwhile, Novartis shares plunged 9.4% following a failed phase 3 trial for del-desiran, even as BrainChild Bio raised $116 million and Bristol Myers Squibb achieved positive trial results for its multiple myeloma therapy.
01Policy
FDA Permanently Appoints Acting Heads for Drug and Vaccine Centers
Permanent leadership at the drug and biologics oversight divisions provides regulatory predictability for biotech pipelines while establishing a dedicated office to accelerate tech-driven trial reviews.
The Trump administration permanently filled four key leadership roles at the Food and Drug Administration on Tuesday. Michael Davis will serve as director of the Center for Drug Evaluation and Research, and Karim Mikhail will take over as director of the Center for Evaluation and Research. Bret Koplow was named director of the Center for Tobacco Products, while Jared Seehafer will serve as the agency's first deputy commissioner for technology and . The appointments stabilize key agency posts as the pushes staff to use artificial intelligence to speed up its review processes.
BrainChild Bio Raises $116M Series A for Pediatric CAR-T Clinical Trial
Direct central nervous system delivery that avoids systemic conditioning chemotherapies removes a primary safety bottleneck, enabling repeatable dosing models that fundamentally alter CAR-T economics.
BrainChild Bio has raised $116 million in a Series A venture financing round to fund for pediatric brain cancer treatments. Spun out of Seattle Children's Hospital research, the biotech is advancing its lead candidate BCB-276 through a Phase 2 trial for diffuse intrinsic pontine glioma, a rare and fatal brain stem tumor affecting about 300 children in the U.S. annually. The financing was led by a private family fund and foundation, with participation from Seattle Children's and WRF . Unlike traditional CAR-T therapies that require a chemotherapy conditioning regimen, BrainChild's approach allows for multiple doses delivered directly to the central nervous system, bypassing systemic side effects. The company is also developing a second program, BCB-214, for glioblastoma and plans to launch human testing for it next year.
New Clinical Decision Support Model Launched Using Six AI Agents
Running containerized mixture-of-experts models locally via air-gapped hardware shifts enterprise AI monetization from recurring API consumption fees toward high-margin, on-premises hardware and infrastructure sales.
Biopharmadive.com reports that a new reference architecture running on the Dell Pro Max with GB300 and the NVIDIA Grace Blackwell Ultra GB300 Superchip deploys six specialized agents on a single deskside system. Purpose-built for research labs and enterprise teams, the setup delivers 20,000 TFLOPS of FP4 computing power and hosts models with up to one trillion parameters entirely on-premises. The configuration deploys a coordinator and five domain experts covering patient data, labs and vitals, medications, clinical analysis, and molecular visualization. At its core, the system runs NVIDIA Nemotron 3 Super, a 120-billion-parameter mixture-of-experts model, locally via containerized inference. This air-gapped deployment allows patient data to be processed locally without passing through external APIs or hosted services, satisfying strict data sovereignty requirements. Rather than competing with existing workflows, the architecture automates tasks such as care gap identification by reading human-readable skill files at query time, letting organizations update clinical thresholds without retraining the underlying model.
Novartis Drops Near Record Low After Failure of Avidity-Acquired Phase 3 Drug Trial
Writing off expensive acquisitions due to late-stage trial failures leaves large pharma dependent on shrinking legacy pipelines to justify historic deal premiums.
Novartis shares fell 9.4% on Tuesday after its late-stage trial for the muscle-wasting drug del-desiran missed its primary endpoint. The HARBOR study showed the drug was statistically no better than placebo at improving hand opening time in patients with myotonic dystrophy type 1. The setback marks the company's third failure in a week, following a failed cardiovascular trial for pelacarsen and a paused cell therapy trial. Del-desiran was acquired as part of Novartis's roughly $12 billion buyout of Avidity Biosciences, where peak annual revenues had been forecast as high as $6 billion. The consecutive trial failures leave the drugmaker evaluating the full dataset while dealing with its worst trading day on record.
Targeting GPRC5D allows cell therapy makers to salvage market share in multiple myeloma patients who have already relapsed on standard BCMA-directed treatments.
Bristol Myers Squibb reached the primary endpoint in a pivotal trial for its GPRC5D-directed CAR-T cell therapy, arlocabtagene autoleucel. The single-treatment Quintessential trial evaluated the overall response rate in patients with multiple myeloma who previously received a BCMA-targeted therapy, an immunomodulatory inhibitor, a proteasome inhibitor, and an anti-CD38 therapy. The therapy also met a key secondary endpoint for complete response rate, though Bristol Myers has not yet released specific trial data or survival outcomes. The drugmaker intends to present detailed results at an upcoming medical meeting, providing a direct comparison against rival treatments like Johnson and Johnson's Talvey. Johnson and Johnson previously reported a 72% overall response rate in its Monumental-1 trial for patients with heavily pretreated multiple myeloma. Bristol Myers is conducting a comparing arlocabtagene autoleucel against standard treatment regimens, with data expected in 2028. The company is evaluating whether to pursue regulatory approval using the Quintessential study despite a Food and Drug Administration requirement for CAR-T developers to demonstrate superiority over existing therapies. Multiple competitors including AbbVie, AstraZeneca, Legend Biotech, and Sanofi are developing molecules targeting GPRC5D.
Biocon Secures 10-Year Pertuzumab Supply Contract in Brazil
Structuring biosimilar entry around Brazil's public partnership model trades eventual technology transfer for immediate procurement exclusivity, replacing volatile drug tenders with long-term sovereign cash flows.
Biocon secured a 10-year supply contract for Pertuzumab in Brazil alongside partners Bahiafarma and Bionovis. The consortium received a 100% allocation under Brazil's productive development partnership program, granting exclusive access to a public healthcare market representing about 70% of the country's demand for the breast cancer therapy. Biocon will collect milestone payments and a share of revenues over the decade, while the drug undergoes phased localization in Brazil. The therapy is currently not manufactured locally and remains a major expenditure for the Unified Health System. Biocon recently reported a consolidated net profit of Rs 141 crore for Q1 FY27 on of Rs 4,336 crore.
Q1 Consolidated Financials (Rs crore)
Revenue reached 4,336 crore alongside 141 crore in net profit for Q1 FY27
Google DeepMind Publishes Human Genome Mutation Predictions to Aid Drug Discovery
By releasing precomputed genome data for free to academia while paywalling commercial use on Google Cloud, DeepMind leverages foundational AI research directly into enterprise cloud consumption.
Google DeepMind published predictions for all nine billion possible single-point mutations in the human genome, releasing the database for academic researchers. The platform, named AlphaGenome Atlas, contains precomputed consequences for every single-letter DNA substitution across human and mouse genomes. Researchers can access the database free for noncommercial use through a new website, while commercial access will be offered through Google Cloud. The model behind the database evaluates how mutations affect gene regulation and protein transcription across hundreds of cell and tissue types. To help researchers prioritize variants, the company also introduced the AlphaGenome Variant Impact score.
Regulatory leadership changes and advanced genomic AI tools offer new technical foundations for the sector. However, sharp trial failures like Novartis's show that high clinical development risks continue to challenge valuation stability.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.